Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00129623 |
This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Condition | Intervention | Phase |
---|---|---|
Post-Menopausal Osteopenia |
Drug: ibandronate [Bonviva/Boniva] Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Double-Blind,Placebo-Controlled,Randomized, Multicenter Study to Assess the Efficiency and Safety of Oral Ibandronate 150 mg Once Monthly in Postmenopausal Women With Osteopenia |
Enrollment: | 160 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: ibandronate [Bonviva/Boniva]
150mg po monthly for 1 year
|
2: Placebo Comparator |
Drug: Placebo
po monthly for 1 year
|
Ages Eligible for Study: | 45 Years to 60 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Colorado | |
LAKEWOOD, Colorado, United States, 80227 | |
United States, Florida | |
STUART, Florida, United States, 34996 | |
United States, Maryland | |
BETHESDA, Maryland, United States, 20817 | |
United States, Michigan | |
DETROIT, Michigan, United States, 48236 | |
United States, Missouri | |
ST LOUIS, Missouri, United States, 63110 | |
United States, Nebraska | |
OMAHA, Nebraska, United States, 68131 | |
United States, New Mexico | |
ALBUQUERQUE, New Mexico, United States, 87106 | |
United States, Ohio | |
CINCINNATI, Ohio, United States, 45224 | |
United States, Oregon | |
PORTLAND, Oregon, United States, 97213 | |
United States, Texas | |
AMARILLO, Texas, United States, 79124 | |
United States, Virginia | |
RICHMOND, Virginia, United States, 23294 | |
NORFOLK, Virginia, United States, 23502 |
Study Director: | Clinical Trials | Hoffmann-La Roche, +1 973 235 5000 |
Responsible Party: | Hoffmann-La Roche ( Clinical Trials, Study Director ) |
Study ID Numbers: | BA18492 |
Study First Received: | August 11, 2005 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00129623 |
Health Authority: | United States: Food and Drug Administration |
Ibandronic acid Musculoskeletal Diseases Bone Diseases, Metabolic Bone Diseases Menopause |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |